CHRS

Coherus Oncology Stock Analysis

AI Rating

Great
  • Quality4/10
  • Growth↑ 9/10
  • Momentum↑ 8/10
Coherus Oncology sales and earnings growth
CHRS Growth
Great
  • Revenue Y/Y↓ -24.15%
  • EPS Y/Y↑ 4533.33%
  • FCF Y/Y↓ -45.50%
Coherus Oncology gross and profit margin trends
CHRS Profitability
Good
  • Gross margin ↑ 47.80%
  • EPS margin↑ 185.40%
  • ROIC↑ 139.50%
Coherus Oncology net debt vs free cash flow
CHRS Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 13.8

Coherus Oncology stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗